James Mock serves as the Chief Financial Officer (CFO) at Moderna Inc., a leading biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA). In his role, Mock is responsible for overseeing the company's financial strategy, planning, and operations, ensuring that Moderna remains financially robust as it pursues its ambitious research and development goals. His leadership has been instrumental in guiding Moderna through its rapid growth, particularly during the global response to the COVID-19 pandemic, where the company's mRNA technology played a pivotal role. Prior to joining Moderna, Mock held several high-profile positions in the financial sector, which equipped him with the expertise needed to excel in his current role. He previously served as the CFO at Alexion Pharmaceuticals, where he was key in driving the company's financial strategy and growth initiatives. Before Alexion, Mock worked at Ernst & Young, where he honed his skills in financial auditing and advisory services. His extensive experience in finance and pharmaceuticals has enabled him to make significant contributions to Moderna's success, including navigating the company through its initial public offering (IPO) and subsequent financings. Under Mock's financial stewardship, Moderna has achieved several milestones, including the successful development and distribution of its COVID-19 vaccine, which has been administered to millions worldwide. His strategic foresight and financial acumen have been crucial in securing the resources needed for Moderna's ongoing research into mRNA therapies for a range of diseases, from infectious diseases to cancer. Mock's role at Moderna is not only about managing the company's finances but also about ensuring that the company remains at the forefront of innovation in the biotech industry.